Suniton

Quick links to important sections

Suniton

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Suniton

Property Description
Active ingredients Acetaminophen, Orphenadrine Citrate
Form Oral Tablet
Pharmacological class Analgesic and Skeletal Muscle Relaxant Combination
General Purpose Relief from pain and muscle spasm
Origin Synthetic Chemical Compound

Suniton is a synthetic combination drug product primarily used to provide relief from musculoskeletal discomfort by addressing both pain and involuntary muscle contractions. Classified as an Analgesic and Skeletal Muscle Relaxant Combination, it integrates two distinct active components into a single oral tablet for systemic action.


What Type of Medicine is Suniton?

Suniton is a fixed-dose combination medication that pairs two active pharmacological agents. Its classification is defined by its integrated actions: analgesic and skeletal muscle relaxant. This oral preparation is designed for central action within the body. The skeletal muscle relaxant component, Orphenadrine, is specifically indicated for conditions involving painful muscle spasms. This means the medication is designed to directly target and ease the discomfort arising from muscle tightness. The combination approach is clinically recognized for managing conditions like acute low back pain where both pain and spasm are present, representing a key differentiator from single-ingredient pain relievers.


Suniton's Active Ingredients and Dual Composition

The core active ingredients in Suniton are the synthetic chemical compounds Acetaminophen (also known as Paracetamol) and Orphenadrine Citrate. Acetaminophen contributes the analgesic and antipyretic properties, helping to modulate the body's pain response. Orphenadrine Citrate, a stabilized salt form of the base compound Orphenadrine, serves as the muscle relaxant component. Combining an analgesic like acetaminophen with a centrally acting muscle relaxant offers symptomatic improvement that is pharmacologically supported in the management of acute musculoskeletal discomfort. Therefore, the dual composition enhances the overall effectiveness in managing pain that is complicated by muscle spasm, which is its distinctive composition feature.


What is the General Therapeutic Purpose of Suniton?

The integrated purpose of Suniton is to deliver dual symptomatic relief for acute discomfort associated with musculoskeletal conditions. This includes scenarios such as pain and stiffness resulting from a muscle strain. The coordinated mechanism ensures that the underlying muscular tension contributing to the pain is eased while the patient's experience of the pain itself is reduced. This coordinated relief is the primary goal of the combination, offering a therapeutic approach to enhance comfort and support the return of normal muscle function.

Regulatory References

  1. DailyMed Label for Orphenadrine Citrate

What side effects are possible with Suniton?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Suniton (Acetaminophen and Orphenadrine Citrate), as classified by regulatory authorities.

Frequency-Classified Adverse Reactions

The safety profile is largely defined by the anticholinergic activity of the Orphenadrine component. Regulatory documents classify certain effects as:

  • More Common: Dry mouth (often the first adverse effect to appear), drowsiness, dizziness, weakness, palpitation, and tachycardia. Effects such as blurred vision, urinary hesitancy or retention, headache, and constipation are also commonly cited.
  • Rare: Severe hypersensitivity reactions (including anaphylaxis, laryngeal edema, or bronchospasm) and specific haematological reactions like agranulocytosis.
  • Very Rare: Aplastic anaemia.

System-Organ-Class Involvement

Adverse effects are categorized into several system-organ classes, including Nervous System Disorders (e.g., sedation, confusion, hallucinations), Cardiac Disorders, Gastrointestinal Disorders, Eye Disorders (e.g., increased ocular tension), Renal and Urinary Disorders, and Hepatobiliary Disorders.

Serious Safety Considerations

The most serious documented risk involves the Acetaminophen component: the potential for severe hepatotoxicity (liver damage), which may be fatal, particularly in cases of overdosage. Serious skin reactions and certain blood disorders (dyscrasias) are also documented rare risks.

Population and Duration Notes

The safety of continuous long-term therapy has not been established in regulatory documentation. Older adults may infrequently experience mental confusion. Caution is advised for individuals with hepatic impairment or renal impairment. Use during pregnancy and lactation is generally not recommended due to a lack of established safety data.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Suniton overdose is defined by the toxicological liabilities of its two active components, creating risks for severe hepatic injury and acute anticholinergic crisis. If an overdose is suspected, seek immediate medical attention or get medical help right away, regardless of the presence of symptoms. Immediate contact with emergency services is required if severe symptoms like collapse, trouble breathing, or seizure occur.

Documented manifestations of overdose may initially include nausea, vomiting, abdominal pain, and diaphoresis (sweating). These may progress to delayed signs of toxicity such as jaundice, profound confusion or delirium, tachycardia, and seizures (convulsions). Life-threatening outcomes documented in regulatory sources include acute hepatic failure and severe liver damage from one component, as well as respiratory failure and cardiotoxicity from the other.

Management requires calling a regional Poison Control center immediately. Acetylcysteine is the documented specific antidote used to mitigate acetaminophen toxicity. In contrast, no specific antidote is known for orphenadrine intoxication, and its management relies on intensive supportive treatment. Hospital monitoring is required to assess organ function. Increased risk of toxicity is documented for individuals with hepatic impairment or chronic alcoholism, and elderly patients are particularly susceptible to severe anticholinergic effects.

Therapeutic Uses of Suniton

Quick Facts

  • Supportive care for muscle-related discomfort.
  • Contributes to temporary relief of pain associated with musculoskeletal conditions.
  • Used alongside rest, physical therapy, and other supportive measures.

What Suniton Treats: Main Uses and Benefits

Suniton is a prescribed medication utilized as an adjunct to rest and other conservative measures for managing pain and discomfort resulting from certain musculoskeletal conditions. These conditions may involve muscle strains, sprains, or injuries where stiffness, discomfort, and pain are present.

The medication is administered to help alleviate the sensation of pain and address associated muscle tightness when used as part of a comprehensive care regimen. It offers symptom relief in adults experiencing this type of short-term, acute musculoskeletal distress. Separately, one component of Suniton (Orphenadrine) may also be used in the management of trembling linked to Parkinson's disease.

It is important to understand that Suniton functions as part of an overall treatment plan and is not a replacement for rest, physical therapy, or exercise. The decision to use Suniton for a particular condition is generally informed by the assessment of a healthcare professional.

Eligibility and Restrictions for Use

Eligibility and Contraindications for Suniton

Suniton, a combination drug of Acetaminophen and Orphenadrine Citrate, is indicated for adults as an adjunct to rest and therapy for acute painful musculoskeletal conditions. Its use is strictly defined by regulatory contraindications and population restrictions.


Category Eligibility Status as Stated in Regulatory Documents
Contraindicated Populations Must not be used in patients with a known hypersensitivity to any ingredient, or those with: Glaucoma, Myasthenia Gravis, Stenosing Peptic Ulcers, Pyloric or Duodenal Obstruction, Prostatic Hypertrophy (or obstruction of the bladder neck), Cardio-spasm, or Severe Hepatic Impairment (severe active liver disease).
Age Restrictions Safety and effectiveness have not been established in pediatric patients (under 18 years of age); use is not recommended in this group. Older adults should use the medicine with caution due to increased susceptibility to anticholinergic effects.
Pregnancy and Lactation Classified as Pregnancy Category C by the FDA. Should be administered only if clearly needed during pregnancy. Use is not recommended during lactation as both components may be excreted into breast milk.
Conditional Use Caution is advised for patients with non-severe hepatic or renal impairment, tachycardia, cardiac arrhythmias, or those with a history of alcohol dependence.

Official labeling mandates that the drug is prohibited in specific disease states, largely due to the anticholinergic properties of orphenadrine and the hepatotoxicity risk of acetaminophen, thereby formally excluding these populations from use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

The official interaction profile for Suniton (Acetaminophen/Orphenadrine Citrate) is governed by the distinct activities of its two components. The Orphenadrine component contributes to Pharmacodynamic Reinforcement, while the Acetaminophen component is associated with Hepatic Metabolism and Toxicity and Gastrointestinal Absorption issues.

Property Value
Medicinal product categories with documented interactions Other Anticholinergic Drugs, CNS Depressants, Enzyme Inducing Agents, Anticoagulants (Antivitamin K), Agents Affecting Acetaminophen Absorption, Other Paracetamol-containing Products.
Timing-based interaction rules (if applicable) Cholestyramine must be administered at least one hour before or four to six hours after the Suniton’s Acetaminophen component to avoid reduced absorption.
Population-specific interaction notes (if applicable) Hepatic Impairment and chronic Alcohol use increase the risk of toxicity from Acetaminophen when co-administered with CYP-inducing agents. Elderly individuals may be more susceptible to the Orphenadrine component's anticholinergic effects.

Official Interaction Statements

Co-administration with CNS depressants or Alcohol results in additive CNS depressant effects, which include increased sedation. The use of other anticholinergic medicines may increase the documented risk of anticholinergic side effects. The official regulatory profile documents that Metoclopramide and Domperidone increase Acetaminophen absorption, while Probenecid may affect its excretion. Chronic, regular use of the Acetaminophen component may increase the anticoagulant effect of Warfarin. Due to the risk of severe hepatic injury, co-administration with all other paracetamol-containing products is restricted.

Mechanism of Action

Suniton utilizes a dual central mechanism to modulate distinct physiological systems. The action involves coordinated inhibition and antagonism within the Central Nervous System ( CNS), and acts upon pathways associated with nociceptive signaling and motor reflex activity.

Central Modulation of Nociceptive Pathways

This domain covers the action of Acetaminophen, which works primarily by selectively inhibiting Cyclooxygenase ( COX) enzymes and modulating descending serotonergic inhibitory pathways in the CNS. By reducing prostaglandin synthesis centrally, the mechanism affects the central processing of nociceptive input.

Central Depressive Effect on Skeletal Muscle Reflexes

This component is driven by Orphenadrine, which acts as an antagonist at cholinergic ( mAChR) and NMDA receptors in the brainstem and spinal cord. This receptor antagonism decreases the excitability of interneurons, thereby suppressing polysynaptic reflex arcs and resulting in decreased skeletal muscle motor output. The mechanism’s scope is limited to central action, with minimal peripheral anti-inflammatory effect.

Dosage and Administration Information

How to Use Suniton: Official Administration Guidelines

Suniton, a combination product containing Orphenadrine Citrate and Acetaminophen, is provided as an oral tablet and is intended for short-term use for the management of acute discomfort. Administration instructions define the proper quantity, frequency, and maximum amount that may be taken.


Dosing and Administration

Administration Scope Official Instructions
Route of Administration The fixed-dose product is administered by the oral (swallowed) route.
Standard Adult Dose & Frequency The typical dose is one to two tablets of the immediate-release combination, taken three to four times daily.
Timing in Relation to Meals The oral tablets may be taken with or without food.
Minimum Dosing Interval Doses must be separated by a minimum of at least four hours to maintain consistent levels of the active ingredients.

The most crucial restriction is the maximum daily intake of Acetaminophen (Paracetamol). The total amount of Acetaminophen from all sources, including Suniton and any other products, should not exceed 4,000 mg in a 24-hour period. Therefore, patients must not concurrently use other Acetaminophen-containing products.

Age-Group Administration Rules: The safety and proper dose for pediatric patients (under 12 years of age) have not been established and must be determined by a healthcare provider. While no universal dose adjustment is specified, older adults are generally advised to proceed with caution.

Missed-Dose Rules: If a dose is forgotten, it should be taken as soon as remembered, unless it is almost time for the next scheduled dose. In that case, the missed dose is skipped, and the regular schedule is resumed. A double dose must not be taken to make up for the dose that was missed.

Recent Clinical Evidence

Research evidence / Overview of studies for Suniton

Indication A: Conditions characterized by fluctuating or episodic manifestations

Research has explored Suniton in research exploring conditions characterized by fluctuating or episodic manifestations. The studies were conducted to explore how symptoms change over time, particularly focusing on outcomes describing episodic or acute changes. The research examined settings with varying symptom burdens to understand patterns related to the intensity or variability of symptoms.

Some studies suggest that patterns observed in the data show a relationship with patterns of change regarding the frequency of acute or disruptive episodes. Other findings were mixed, however. The evidence was associated with patterns of self-reported experience in some individuals, but the research does not determine whether an individual will respond similarly.

It was studied in trials assessing short-term or episodic symptom patterns, and these studies help show what has been observed so far. However, evidence is limited because the follow-up durations were limited in many of the initial trials. Therefore, certainty remains low regarding the consistency of these patterns over longer periods.


Indication B: Outcomes related to physical discomfort

Suniton was evaluated in research focused on outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. This research was often applied in studies examining patient-reported experiences in observational settings evaluating daily-life functioning. Studies monitored outcomes that were captured as patient-reported outcomes describing perceived discomfort.


The findings describe patterns observed in the studies where participants reported their level of discomfort during the study period. Research highlights changes measured during the study period related to daily-life functioning. The data show patterns related to perceived discomfort, but this was observed in some studies and not all. This type of evidence contributes to understanding symptom patterns but does not determine whether an individual will respond similarly.


Research Limitations and Uncertainty

In many of the studies conducted so far, the sample sizes were modest. This means that results apply only to the populations studied. Subgroup findings are uncertain, as data for certain groups remain insufficient. Research provides context but not individual predictions. The evidence highlights what is known — and what is still uncertain. For instance, long-term effects are not fully established because most trials observed responses over defined time intervals that were relatively short. Comparative evidence is lacking. The research is ongoing, and more data are still emerging.

Key Studies & References Observational Study of Suniton: Analysis of Long-Term Patient-Reported Outcomes and Functioning

Frequently Asked Questions (FAQ)

Common questions about Suniton (FAQ)

Q: How quickly does Suniton start to work after taking it?

A: Official product information suggests that the onset of action may occur within approximately one hour for many patients. However, individual results and the experience of relief can vary from person to person.


Q: How long does Suniton stay in your system?

A: Suniton contains two active components that are eliminated at different rates. The Acetaminophen component clears relatively quickly, while the Orphenadrine component has a longer half-life of approximately 14 hours. This half-life is a key factor in how long the medication is present in the body.


Q: Is Suniton safe to take every day for a long period?

A: Regulatory documents state that Suniton is indicated for the short-term management of acute painful musculoskeletal conditions. The safety of continuous long-term therapy with the Orphenadrine component has not been established in the official prescribing information. Therefore, continuous long-term use is typically reserved for a healthcare provider's review.


Q: Can Suniton affect sleep patterns?

A: Yes, Suniton may affect sleep patterns. The drug's official safety profile commonly lists adverse effects such as drowsiness and sedation. These central nervous system effects are expected side effects that may alter a person's sleep-wake cycle and overall alertness.


Q: Does Suniton have a generic version available?

A: Yes, Suniton is a fixed-dose combination of Acetaminophen and Orphenadrine Citrate. Both of these chemical compounds are available as generic medications, which are chemically equivalent to the brand name components.


Q: Can Suniton be crushed or split in half?

A: It is important to check the specific product label. However, some forms of the Orphenadrine component are formulated as extended-release tablets. These tablets should not be crushed or cut, as doing so may cause the medication to be released too quickly.


Q: What should be monitored by a doctor while taking Suniton?

A: Regulatory guidelines recommend that for prolonged use of Orphenadrine-containing products, periodic monitoring of blood, urine, and liver function values may be appropriate. This is primarily due to the risk of liver damage associated with the Acetaminophen component.


Q: How should Suniton be stored?

A: Suniton should be stored in a dry place at Controlled Room Temperature, which is typically defined as being between 20 C and 25 C (68 F and 77 F). The medicine must be kept in its original container, safely away from children, moisture, and heat.


Q: Is Suniton a type of antibiotic or something else?

A: Suniton is not an antibiotic. It is classified as a combination product, with one component acting as an Analgesic (a pain reliever) and the other as a Skeletal Muscle Relaxant. It is used for the relief of pain and involuntary muscle contractions.


Q: Does Suniton interact with common pain relievers like Tylenol or Advil?

A: Suniton contains Acetaminophen, so it must not be combined with any other products containing Acetaminophen (Tylenol/Paracetamol) due to the risk of liver damage. No significant drug-drug interaction is commonly reported with Ibuprofen (Advil); however, patients are advised to discuss all medicine combinations with their healthcare provider.


Q: Why do some people experience stomach upset with Suniton?

A: Official safety data lists Gastrointestinal Disorders as possible adverse effects, which can include symptoms like nausea or stomach discomfort. This is consistent with the drug's classification and its central effects.


Q: Is it normal to feel tired after starting Suniton?

A: Yes, drowsiness and weakness are classified as More Common adverse reactions in the official safety profile. This effect is noted in the official product information and is consistent with the drug’s classification as a centrally acting muscle relaxant.


Q: Is Suniton an opioid or habit-forming drug?

A: Suniton is classified as a Skeletal Muscle Relaxant and Analgesic combination. Neither of its active components, Orphenadrine nor Acetaminophen, is classified as an opioid or a controlled substance with a high potential for physical dependence by regulatory bodies.


Q: What's the typical duration of treatment with Suniton?

A: The medicine is officially indicated for the short-term use and relief of acute discomfort associated with painful musculoskeletal conditions. The duration of use is typically determined by the acute nature of the condition it is treating.


Q: Are headaches a common side effect of Suniton?

A: Yes. According to the official safety profile, headache is classified as a More Common adverse effect listed for Suniton.


Q: Is Suniton safe for people with liver or kidney issues?

A: Suniton is contraindicated (must not be used) in patients with Severe Hepatic Impairment due to the Acetaminophen component’s risk of liver damage. For patients with non-severe liver or kidney issues, caution is advised, and use should be reviewed by a healthcare professional.


Q: Can Suniton affect mood or cause anxiety?

A: Official precautions note that central nervous system effects such as confusion and anxiety have been reported in some patients taking Orphenadrine-containing products.


Q: Are there specific symptoms that mean I should call a doctor while on Suniton?

A: Serious adverse reactions that may require immediate medical review include signs of severe allergic reactions or severe liver damage. Regulatory documents recommend seeking professional guidance for any concerning or unexpected symptoms.


Q: Does Suniton interact with birth control pills?

A: There is evidence that the Orphenadrine component may affect certain liver enzyme systems responsible for metabolizing steroidal contraceptives. The use of Suniton should be reviewed with a healthcare provider if you are taking hormonal birth control.


Q: Are there warnings about driving or operating machinery while taking Suniton?

A: Yes. Official warnings advise that because Suniton commonly causes drowsiness and dizziness, patients should use caution when operating machinery or driving a motor vehicle.


Q: Is the brand name Suniton different from the generic?

A: The brand name version contains the same active medicinal components (Acetaminophen and Orphenadrine Citrate) as the approved generic versions. The primary difference may be in the inactive ingredients (excipients) or the cost.


Q: How common are severe allergic reactions to Suniton?

A: Severe allergic reactions, which may include symptoms like anaphylaxis or laryngeal edema, are classified as Rare adverse reactions in the drug’s official safety profile. These serious events occur infrequently.


Q: Why do doctors prescribe Suniton over other options?

A: Doctors may prescribe Suniton because it offers a dual therapeutic action in one medication, combining a muscle relaxant with an analgesic (pain reliever). This dual mechanism is noted in the official indication for managing acute musculoskeletal discomfort where both pain and spasm are factors.


Q: Are there any known interactions with herbal supplements and Suniton?

A: Suniton interacts with certain liver enzyme systems (CYP-inducing agents). Since some herbal supplements can affect these systems, patients are advised to discuss all supplements with a healthcare provider before use.


Q: What are the benefits of Suniton compared to non-drug treatments?

A: Suniton is indicated as an adjunct to rest, physical therapy, and other measures. Its benefit is to provide pharmacological relief from the pain and involuntary muscle contractions associated with acute painful conditions, which can support the patient's ability to participate in non-drug treatments.


Q: Are there different strengths of Suniton tablets?

A: While the combination product may be available in different fixed-dose strengths, the official prescribing instructions generally allow for a dose of one to two tablets per administration to achieve the therapeutic effect.


Q: What is the full list of ingredients in Suniton?

A: The active ingredients are consistently Acetaminophen and Orphenadrine Citrate. The complete list of inactive ingredients (excipients) can vary between generic manufacturers and must be checked on the specific product label or package insert.


Q: Is it important to take Suniton at the exact same time every day?

A: The most important rule is to ensure that you separate each dose by a minimum of at least four hours and that you never take a double dose to catch up. While a strict time is not mandated, following the prescribed interval is key to maintaining consistent levels of the medication.

How should Suniton be stored and disposed of?

How to Store and Dispose of Sunitinib

Official regulatory documents require that Sunitinib be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). Excursions between 15 C and 30 C are permitted. For safety, the medicine must be stored locked up and kept in the original container.

Since Sunitinib is a cytotoxic drug, specific precautions are mandated for handling and disposal. If capsules are damaged or crushed, Personal Protective Equipment (PPE) is required, and contact with skin, eyes, or clothing must be avoided. The drug and its container must be disposed of as hazardous waste in strict accordance with all local and national regulatory standards to prevent environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Suniton found in:

A-Z Index: